276 related articles for article (PubMed ID: 2455910)
1. Poor prognosis germ cell tumors of the testes: improved results with high dose regimens.
Ozols RF
Prog Clin Biol Res; 1988; 269():419-27. PubMed ID: 2455910
[No Abstract] [Full Text] [Related]
2. A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancer.
Stoter G; Sylvester R; Sleijfer DT; ten Bokkel Huinink WW; Kaye SB; Jones WG; van Oosterom AT; Vendrik CP; Spaander P; de Pauw M
Prog Clin Biol Res; 1988; 269():381-93. PubMed ID: 2455909
[No Abstract] [Full Text] [Related]
3. Studies of the Australasian Germ Cell Trial Group: the management of advanced testis cancer.
Raghavan D; Levi J; Thomson D; Harvey V
Prog Clin Biol Res; 1990; 350():319-29. PubMed ID: 1696742
[No Abstract] [Full Text] [Related]
4. [Chemotherapy of disseminated germ cell tumors of the testis].
Tiuliandin SA
Sov Med; 1987; (11):78-81. PubMed ID: 2451298
[No Abstract] [Full Text] [Related]
5. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
Brada M; Horwich A; Peckham MJ
Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
[TBL] [Abstract][Full Text] [Related]
6. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.
Williams SD; Birch R; Einhorn LH; Irwin L; Greco FA; Loehrer PJ
N Engl J Med; 1987 Jun; 316(23):1435-40. PubMed ID: 2437455
[TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
8. Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?
Bokemeyer C
J Clin Oncol; 2008 Apr; 26(11):1783-5. PubMed ID: 18398143
[No Abstract] [Full Text] [Related]
9. Alternatives to standard BEP x 3 in good-prognosis germ cell tumors--you bet your life.
Nichols C; Kollmannsberger C
J Natl Cancer Inst; 2010 Aug; 102(16):1214-5. PubMed ID: 20631340
[No Abstract] [Full Text] [Related]
10. The role of ifosfamide in the treatment of nonseminomatous testicular cancer.
Scheulen ME; Niederle N; Kath R; Wandl UB; Seeber S; Schmidt CG
Prog Clin Biol Res; 1988; 269():439-50. PubMed ID: 2455912
[No Abstract] [Full Text] [Related]
11. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of advanced testicular cancer].
Murase T; Takashi M; Sobashima T; Shimoji T; Miyake K; Mitsuya H
Hinyokika Kiyo; 1987 Jan; 33(1):47-50. PubMed ID: 2437779
[TBL] [Abstract][Full Text] [Related]
15. Management of good risk germ-cell tumours.
Troost MM; Sternberg CN; de Wit R
BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy in nonseminomatous germ cell cancer.
Kollmannsberger C; Beyer J; Bokemeyer C
BJU Int; 2009 Nov; 104(9 Pt B):1398-403. PubMed ID: 19840020
[No Abstract] [Full Text] [Related]
17. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer.
de Haas EC; Zwart N; Meijer C; Nuver J; Boezen HM; Suurmeijer AJ; Hoekstra HJ; van der Steege G; Sleijfer DT; Gietema JA
J Clin Oncol; 2008 Apr; 26(11):1817-23. PubMed ID: 18398146
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
[TBL] [Abstract][Full Text] [Related]
19. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
20. Cancer of the testis: a new paradigm.
Einhorn LH
Hosp Pract (Off Ed); 1986 Apr; 21(4):165-72, 175-8. PubMed ID: 2420812
[No Abstract] [Full Text] [Related]
[Next] [New Search]
